Metabolic plasticity in melanoma progression and response to oncogene targeted therapies

Abstract

Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experimental settings have highlighted a range of non‐genetic adaptive mechanisms that contribute to therapy resistance and disease relapse, including transcriptional, post‐transcriptional and metabolic reprogramming. A growing body of evidence highlights the inherent plasticity of melanoma metabolism, evidenced by reversible metabolome alterations and flexibility in fuel usage that occur during metastasis and response to anti‐cancer therapies. Here, we discuss how the inherent metabolic plasticity of melanoma cells facilitates both disease progression and acquisition of an..